Treatment of Parkinson's Disease Dementia

Efficacy and Benefits

• Rivastigmine provides statistically significant and clinically important benefits in global cognitive assessment in patients with Parkinson's disease dementia, particularly for those with rapid cognitive decline 1, 2
• Treatment duration in clinical trials ranged from 14 to 52 weeks, with rivastigmine showing benefits in patients with rapid cognitive decline and vascular risk factors 1, 2, 3
• The American Academy of Neurology recommends rivastigmine patch over donepezil for patients with rapid cognitive decline or vascular risk factors, due to superior outcomes in these patients 2

Safety and Adverse Events

• Common adverse events associated with rivastigmine include vomiting (relative risk 6.06), weight loss, decreased appetite, and dizziness (relative risk 2.24) 1, 3
• Withdrawal rates due to adverse events range from 12-29% in treatment groups, compared to 0-11% in placebo groups 1, 3
• Cholinesterase inhibitors, including donepezil, can contribute to falls due to adverse effects such as dizziness, and should be discontinued in patients who have experienced a fall, as recommended by the American Geriatrics Society and the Mayo Clinic 4, 5
• Donepezil can cause bradycardia, nightmares, and dizziness, increasing fall risk, especially when taken at bedtime or in combination with beta-blockers, as reported by the American College of Clinical Pharmacology and the American Academy of Neurology 4, 5, 1

Long-term Effects and Treatment Considerations

• Long-term effects of rivastigmine beyond 7 months are not well established, and the clinical significance of its benefits varies across studies 1, 3
• Effects on behavior and quality of life were not statistically significant in most studies 1, 3
• The American Academy of Neurology recommends considering memantine as an alternative treatment, due to its potentially more favorable side effect profile in patients with fall risk 6
• The following medications have different hepatotoxicity profiles:

7

• Therapeutic response should be assessed 6-12 months after treatment initiation, and consideration should be given to discontinuing the medication if side effects persist or if the patient's condition continues to deteriorate at the same rate as before treatment, as recommended by the American Academy of Neurology, American Academy of Family Physicians, and American Geriatrics Society 1, 8, 3
• Strategies to minimize side effects include increasing the dose after a longer period, taking the medication with food, and temporarily reducing the dose if intolerable side effects occur, as recommended by the American Geriatrics Society and the American Academy of Neurology 1

Special Considerations

• Women who are pregnant or actively trying to conceive should not use certain medications due to inadequate safety data, as recommended by the American Diabetes Association 9
• Nursing mothers should not use certain medications due to inadequate safety data, as recommended by the American Diabetes Association 9
• Women of reproductive potential should use reliable contraception when using certain medications, as recommended by the American Diabetes Association 9
• For patients with REM sleep behavior disorder and cognitive impairment, Rivastigmine may be beneficial, according to the American Academy of Sleep Medicine 10